A Phase II Study of Cetuximab (Erbitux(R)) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer.
10.3346/jkms.2007.22.S.S98
- Author:
Dong Hoe KOO
1
;
Jae Lyun LEE
;
Tae Won KIM
;
Heung Moon CHANG
;
Min Hee RYU
;
Sung Sook LEE
;
Min Kyoung KIM
;
Sun Jin SYM
;
Jung Shin LEE
;
Yoon Koo KANG
Author Information
1. Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ykkang@amc.seoul.kr
- Publication Type:Original Article ; Clinical Trial, Phase II ; Research Support, Non-U.S. Gov't
- Keywords:
Cetuximab;
Irinotecan;
Oxaliplatin;
Chemotherapy;
Colorectal Neoplasms
- MeSH:
Adult;
Aged;
Antibodies, Monoclonal/*administration & dosage/adverse effects;
Antineoplastic Agents/*administration & dosage/adverse effects;
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse;
Camptothecin/administration & dosage/adverse effects/analogs & derivatives;
Colorectal Neoplasms/*drug therapy/secondary;
Drug Resistance, Neoplasm;
Female;
Fluorouracil/administration & dosage/adverse effects;
Humans;
Leucovorin/administration & dosage/adverse effects;
Male;
Middle Aged;
Organoplatinum Compounds/pharmacology;
Prognosis;
Receptor, Epidermal Growth Factor/antagonists & inhibitors;
Safety
- From:Journal of Korean Medical Science
2007;22(Suppl):S98-S103
- CountryRepublic of Korea
- Language:English
-
Abstract:
We have evaluated the efficacy and safety of cetuximab plus FOLFIRI for irinotecan and oxaliplatin-refractory colorectal cancers. From September 2004 to February 2006, 31 patients with metastatic colorectal cancer were treated with cetuximab (400 mg/m2 intravenously [IV] over 2 hr on day 1 followed by weekly 1-hr infusions of 250 mg/m2) plus bi-weekly FOLFIRI (irinotecan 150 mg/m2 IV over 90 min, and leucovorin 100 mg/m2 IV over 2 hr, followed by 5-FU 400 mg/m2 IV bolus on day 1, and followed by 5-FU 2,400 mg/m2 by continuous IV over 46 hrs). Patients received a median of four cycles (range: 1-23). Eight (25.8%) patients had confirmed partial responses and 10 (32.2%) had stable disease. After a median follow-up of 13.2 months for surviving patients, the median time to progression was 2.9 months, the median duration of response was 5.4 months, and the median overall survival was 10.9 months. Skin toxicity was observed in 25 patients (80.4%) including grade 3 in 6 patients (19.4%). Other common non-hematologic toxicities of all grades were mucositis (32.3%), asthenia (22.6%), diarrhea (12.9%), and paronychial cracking (12.9%). The combination of cetuximab with FOLFIRI was effective and tolerable in colorectal cancer patients heavily pretreated with a number of chemotherapy regimens.
